These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23458352)

  • 1. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression.
    Dudeja V; Greeno EW; Walker SP; Jensen EH
    HPB (Oxford); 2013 Sep; 15(9):661-7. PubMed ID: 23458352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer.
    Tran Cao HS; Balachandran A; Wang H; Nogueras-González GM; Bailey CE; Lee JE; Pisters PW; Evans DB; Varadhachary G; Crane CH; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Gastrointest Surg; 2014 Feb; 18(2):269-78; discussion 278. PubMed ID: 24129826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of borderline and locally advanced pancreatic cancer: where do we stand?
    He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
    World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
    McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
    HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography-based vascular burden index as a predictor of vascular resection and pathological vascular invasion in pancreatic cancer with neo-adjuvant chemotherapy.
    Lee W; Park HJ; Lee YN; Sung MK; Hong K; Park Y; Song KB; Lee JH; Hwang DW; Kim HJ; Hong SM; Kim SC
    Eur J Surg Oncol; 2024 Sep; 50(9):108494. PubMed ID: 38968855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
    Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
    J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining venous involvement in borderline resectable pancreatic cancer.
    Chun YS; Milestone BN; Watson JC; Cohen SJ; Burtness B; Engstrom PF; Haluszka O; Tokar JL; Hall MJ; Denlinger CS; Astsaturov I; Hoffman JP
    Ann Surg Oncol; 2010 Nov; 17(11):2832-8. PubMed ID: 20725860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
    van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
    HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer.
    Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Wakamatsu S; Hoshi S; Hoshi N; Hirabayashi K; Ogata Y
    Eur J Surg Oncol; 2017 Jun; 43(6):1068-1075. PubMed ID: 28427822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.
    Varadhachary GR; Tamm EP; Abbruzzese JL; Xiong HQ; Crane CH; Wang H; Lee JE; Pisters PW; Evans DB; Wolff RA
    Ann Surg Oncol; 2006 Aug; 13(8):1035-46. PubMed ID: 16865597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tumour score with multidetector spiral CT for venous infiltration in pancreatic cancer: influence on borderline resectable.
    Marinelli T; Filippone A; Tavano F; Fontana A; Pellegrini F; Köninger J; Richter GM; Bonomo L; Büchler MW; di Sebastiano P; di Mola FF
    Radiol Med; 2014 May; 119(5):334-42. PubMed ID: 24619824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.